MaaT Pharma

📄 [Press release] – MaaT Pharma is proud to announce that the final patient has been treated in the Phase 3 ARES clinical trial evaluating MaaT013 in treating acute Graft-versus-Host Disease (#aGvHD). Key highlights: ▪ Topline results expected in January 2025 ▪ Positive DSMB review with a favorable benefit/risk ratio noted for its high efficacy and low toxicity ▪ Registration process to commence in Europe in 2025 Our CEO, Hervé Affagard, shared: “We are confident that MaaT013 could become the first-ever approved therapy using microbiome-driven immune modulation in oncology.” 👉https://lnkd.in/emTAdyqE Stay tuned for further updates as we advance towards our goal of improving outcomes for patients with aGvHD. #microbiome #clinicaltrials #oncology #GvHD #innovation #MaaT013 #immunemodulation

📅 [EVENT] – Over the next two months, MaaT Pharma will be participating in two leading hemato-oncology conferences: the #SFGMTC Congress & the American Society of Hematology Annual Meeting. We look forward to discussing the potential of gut microbiota in enhancing survival outcomes for patients with Graft-versus-Host Disease (#GvHD) and for those undergoing allogeneic hematopoietic stem cell transplantation (#HSCT).  #SFGMTC #ASH2024 #alloHSCT #Oncology #Hematology #aGvHD #Microbiome Sabine Kacel Alex KISS, PharmD, MSc Jonathan CHRIQUI Emilie Plantamura Gianfranco Pittari, MD PhD

📢[#SEHH2024] – We were honored to see Dr. Jaime Sanz Caballer present promising data on MaaT013 from our Early Access program at the Sociedad Española de Hematología y Hemoterapia (SEHH) Congress. Based on data from 140 patients treated for acute Graft-versus-Host Disease (#aGvHD), MaaT013 demonstrated a clear reduction in disease burden and improved Overall Survival (OS), with a 12-month survival rate of 42% compared to only 15% in published data (Abedin et al., Br J Haematol, 2021).    Further investigations are currently ongoing in a phase 3 trial for MaaT013 in aGvHD, with patient recruitment now complete. Stay tuned for topline results!     #acuteGvHD #SEHH #SETH #Hematology #Cancer #Microbiome #EarlyAccessProgram #GvHD    For more details, you can access the data presented in April 2024 at the EBMT Annual meeting: link in first comment 👇 

🎥 Dans ce numéro spécial du Journal des Biotechs de Boursorama, Herve Affagard, MBA, Eng., CEO et co-fondateur de MaaT Pharma, fait le point sur la fin des recrutements de l'essai clinique de Phase 3 dans la maladie aiguë du greffon contre l’hôte (aGvH) pour MaaT013 et précise les prochaines étapes. Pour en savoir plus sur les perspectives et la stratégie de MaaT Pharma, découvrez l'interview complète menée par Laurent Grassin : https://lnkd.in/esRjZUuZ #biotech #microbiote #Hématologie #cancer #oncologie

📅- [#Event] – Meet Jonathan CHRIQUI, Chief Business Officer at MaaT Pharma, at #BIO-Europe, on November 4-6, 2024, in Stockholm.   We are eager to connect with global life science leaders and explore exciting collaboration opportunities driving innovation!   #Pharma #Innovation #Biotech #BIO-Europe   For more information, see link in first comment 👇

📢[#SEHH2024] - We are proud to announce that Dr. Jaime Sanz Caballer, will present promising data from our Early Access program where 140 patients were treated with acute Graft-versus-Host Disease (#aGvHD) with MaaT013, our lead asset currently in a fully recruited Phase 3 trial. These encouraging results provide renewed hope for patients with limited treatment options! The data were also shared earlier this year at the EBMT Annual Meeting in April 2024.    Want to learn more? Join the Sociedad Española de Hematología y Hemoterapia (SEHH) Congress, October 24-26, at the Palacio de Congresos de Palma!    #acuteGvHD #SEHH #SETH #Hematology #Cancer #Microbiome #EarlyAccessProgram    For further details, check the link in the first comment 👇 

📄 [Communiqué de presse] – MaaT Pharma est fier d’annoncer le traitement du dernier patient dans l'essai clinique de Phase 3 ARES dans le traitement de la maladie aiguë du greffon contre l’hôte (#aGvH). Points clés : ▪ Publication des premiers résultats désormais attendue en janvier 2025 ▪ Avis positif du DSMB pour l'essai de Phase 3 ARES au T4 2023, avec un rapport bénéfice/risque favorable et une « efficacité élevée et faible toxicité » ▪ Initiation du processus d'enregistrement avec une soumission prévue en 2025 en Europe Notre directeur général, Hervé Affagard, déclare : « Nous sommes convaincus que MaaT013 pourrait devenir la première thérapie approuvée permettant la modulation immunitaire induite par le microbiote en oncologie » 👉https://lnkd.in/e2tUYkJU Continuez à suivre nos actualités, alors que nous poursuivons notre mission dédiée à améliorer la survie des patients atteints de cancer. #microbiote #essaiscliniques #oncologie #GvH #innovation #MaaT013 #modulationimmunitaire #aGvH #Phase3

📅- [#Event] – Meet Sian Crouzet, Chief Financial Officer at MaaT Pharma, and Guilhaume Debroas, Ph.D., Head of Investor Relations at MaaT Pharma, during the Investor Access Forum, on October 15 & 16, 2024, at MAISON DE LA CHIMIE, Paris.   Looking forward to sharing our development with you!   #IR #Investors #Biotech   For more information, see link in first comment 👇

📅- [#Event] – Guilhaume Debroas, Ph.D., Head of Investor Relations at MaaT Pharma, will participate at the Portzamparc Groupe BNP Paribas’ digital Conference on Biotech and Life Sciences, on October 8 & 9, 2024.   A 100% digital meeting place dedicated to institutional customers!   #SeminaireBiotech #Investments #DigitalEvent #Investors #LifeSciences   For more information, see link in first comment 👇

📢 [#JobOpening] - Join the #Production & #Industrialization department of MaaT Pharma as a Medical Devices Industrialization Specialist (M/F)!   🎯 Do you have a Master's degree in biomedical engineering, biotechnology or equivalent, a successful project management experience, and expertise in medical devices, biomaterials, and regulations? If so, this opportunity is for you!   💼 Your main responsibilities: - Technical project management - Documentation and compliance - Risk analysis and production - Communication and innovation   📌 You will be integrated into a dynamic and passionate team dedicated to bringing innovations to improve the survival of patients with cancer.   👉 Send your resume and cover letter to careers@maat-pharma.com to apply now! 🔬 Detailed job description: see link in first comment 👇 📰- Permanent Contract 📍- Saint Quentin Fallavier (38) 🗓️- Position available immediately #Industrialisation #Production #Supply #Biotech Cécile BILLA NYS Clément ROBERT Elsa Bernard Alexia Berthaud Claire Tixier Guillaume PAIR Mélanie RUEZ Lucas Chamam Anthony Martin